A phase IB/IL study of gemcitabine and docetaxel in combination with pazopanib for the neoadjuvant treatment of soft tissue sarcomas

Oncologist

Volumn 20, Issue 11, 2015, Pages 1245-1246

  Munhoz, Rodrigo R ^a   D’Angelo, Sandra P ^a,b   Gounder, Mrinal M ^a,b   Keohan, Mary L ^a,b   Chi, Ping ^a,b   Carvajal, Richard D ^c   Singer, Samuel ^a,b   Crago, Aimee M ^a,b   Landa, Jonathan ^a,b   Healey, John H ^a,b   Qin, Li Xuan ^a,b   Hameed, Meera ^a,b   Ezeoke, Mariettao ^a   Singh, Arun S ^d   Agulnik, Mark ^e   Chmielowski, Bartosz ^d   Luke, Jason J ^f   Vantine, Brian A ^g   Schwartz, Gary K ^c   Tap, William D ^a,b   Dickson, Mark A ^a,b   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Department of Medicine   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DOCETAXEL; GEMCITABINE; PAZOPANIB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TAXOID;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; FATIGUE; FEMALE; HOARSENESS; HUMAN; HUMAN TISSUE; HYPERTENSION; LYMPHOCYTOPENIA; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; TOXICITY; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE FREE SURVIVAL; NEOADJUVANT THERAPY; PATHOLOGY; SARCOMA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PYRIMIDINES; SARCOMA; SULFONAMIDES; TAXOIDS; TREATMENT OUTCOME;

EID: 84946553342     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0245     Document Type: Article

References (0)